Myriad Genetics | MYGN - Equity Capital And Reserves


Myriad Genetics reported $368M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agilent USD 6.91B 167M Dec/2025
Becton, Dickinson and Co. USD 25.28B 108M Dec/2025
Bio-Rad Laboratories USD 7.45B 716.8M Dec/2025
Bruker USD 2.49B 625.6M Sep/2025
Danaher USD 52.95B 415M Mar/2026
Illumina USD 2.72B 342M Dec/2025
J&J USD 81.19B 358M Mar/2026
Mettler Toledo International USD -23.64M 225.56M Dec/2025
Myriad Genetics USD 368M 4.8M Dec/2025
OraSure Technologies USD 340.83M 21.15M Dec/2025
Pacific Biosciences Of California USD 5.35M 30.74M Dec/2025
Quest Diagnostics USD 7.37B 196M Mar/2026
Quidel USD 1.92B 115.9M Dec/2025
Repligen USD 2.11B 1.66B Dec/2025
Revvity USD 7.38B 180.27M Sep/2025
Standard Biotools USD 424.29M 24.63M Dec/2025
Thermo Fisher Scientific USD 53.54B 2.38B Dec/2025
Veracyte USD 1.26B 36.61M Sep/2025
Waters USD 2.56B 230.55M Dec/2025